Bushe Chris, Haddad Peter, Peveler Robert, Pendlebury John
Eli Lilly and Company Limited, Basingstoke, UK.
J Psychopharmacol. 2005 Nov;19(6 Suppl):28-35. doi: 10.1177/0269881105058682.
The recognition that schizophrenia is associated with metabolic comorbidity and a subsequent greater risk of cardiovascular events compared to the general population has led to attempts to reduce this metabolic burden. Increased weight, and smoking rates combined with less exercise and poor dietary choices, have led to a variety of behavioural programmes and pharmacological agents being evaluated with the aim of improving lifestyle and managing weight. Adjunctive pharmacological strategies for weight management have not been shown to be consistently effective and remain contraindicated in many schizophrenia subjects. However some novel compounds with recent promising data suggest that research should not be abandoned. In contrast a variety of behavioural interventions have shown a consistent degree of success not only with weight management but also in achieving lifestyle changes. Many reported data-sets are naturalistic or open-label indicating that there is a difficulty in performing traditional randomized controlled studies in this area. The long-term naturalistic studies and holistic approaches show that weight management and significant lifestyle changes are attainable goals in schizophrenia patients. Weight management and lifestyle advice should be routinely offered to all schizophrenia subjects.
与普通人群相比,精神分裂症与代谢合并症相关且随后发生心血管事件的风险更高,这一认识促使人们试图减轻这种代谢负担。体重增加、吸烟率上升,再加上运动减少和不良的饮食选择,导致人们对各种行为方案和药物进行评估,旨在改善生活方式和控制体重。辅助性体重管理药物策略尚未被证明始终有效,并且在许多精神分裂症患者中仍然是禁忌的。然而,一些有近期 promising 数据的新型化合物表明研究不应被放弃。相比之下,各种行为干预不仅在体重管理方面,而且在实现生活方式改变方面都显示出一致程度的成功。许多报告的数据集是自然主义的或开放标签的,这表明在该领域进行传统的随机对照研究存在困难。长期的自然主义研究和整体方法表明,体重管理和显著的生活方式改变是精神分裂症患者可以实现的目标。应常规向所有精神分裂症患者提供体重管理和生活方式建议。